Researchers have discovered unique populations of neurons in the spinal cords of patients who died of amyotrophic lateral sclerosis that could be utilized as potential drug targets.
Browsing: drug development
Recommendations for classification of commercial LBA kits for biomarkers in drug development from the GCC for bioanalysis
In this White Paper from Bioanalysis the authors highlight the need the bioanalytical community has for commercial kits able to be used for regulated drug development.
This commentary from Bioanalysis focuses on the status of drug detection with metal nanoparticles as ultrasmall labels in colorimetric-based methods.
Global leaders in life sciences and nonclinical drug development, Envigo (Huntingdon, UK) and LabCorp (NC, USA), have signed an innovative agreement in a bid to expand nonclinical drug development capabilities and create an independent research models provider.
In this editorial Yu Shrike Zhang (Harvard Medical School; MA, USA), a previous finalist of the Bioanalysis Rising Star Award, discusses his research and hopes for the future. He details the emergence of organ-on-a-chip systems and how these platforms reproduce tissue functions outside the human body.
As part of our focus, we present this podcast where we talk to Mark Savage who discusses how software tools can address certain challenges and bring forward compounds from discovery to development.
The future of individualized medicine: intensified decentralized biotherapeutic production in combination with state-of-the-art diagnostics of the next generation
In this editorial the future of individualized medicine is reviewed, focusing on the decentralization of biotherapeutic production in combination with state-of-the-art diagnostics of the next generation.
In this interview, John Kellie (GSK, PA, USA) discusses the technologies that he uses on a regular basis. He explains how large molecule bioanalysis influences downstream drug development and his future outlook on where the field will be in 5–10 years’ time.
Quantitative whole body autoradiography (QWBA) and imaging mass spectrometry (IMS): can IMS replace QWBA to support regulated drug discovery and development
Read time: 4:45 mins
Eric Solon (Madrigal Pharmaceuticals; PA, USA) discusses whether or not IMS can replace QWBA as the technique of choice when examining the disposition of new drug and biotherapeutic entities.
In this installment of Robert MacNeill’s (Envigo) column, Robert discusses the instability of drugs within samples and how to balance their instability against absorptive loss.